169 related articles for article (PubMed ID: 29788416)
21. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?
Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140
[TBL] [Abstract][Full Text] [Related]
22. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
23. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
[TBL] [Abstract][Full Text] [Related]
24. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
Crandall WV; Mackner LM
Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
[TBL] [Abstract][Full Text] [Related]
25. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
[TBL] [Abstract][Full Text] [Related]
26. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study.
Mälkönen T; Wikström A; Heiskanen K; Merras-Salmio L; Mustonen H; Sipponen T; Kolho KL
Inflamm Bowel Dis; 2014 Aug; 20(8):1309-15. PubMed ID: 24918318
[TBL] [Abstract][Full Text] [Related]
27. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
[TBL] [Abstract][Full Text] [Related]
29. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
[TBL] [Abstract][Full Text] [Related]
30. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis.
Picoraro J; Winberry G; Siegel CA; El-Matary W; Moses J; Grossman A; Park KT
Inflamm Bowel Dis; 2017 Jan; 23(1):174-180. PubMed ID: 28002131
[TBL] [Abstract][Full Text] [Related]
31. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in inflammatory bowel disease. Is premedication necessary?
Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
[TBL] [Abstract][Full Text] [Related]
33. Rapid infliximab infusions in pediatric inflammatory bowel disease.
Yeckes AR; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):151-4. PubMed ID: 19516188
[TBL] [Abstract][Full Text] [Related]
34. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
[TBL] [Abstract][Full Text] [Related]
35. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.
Fumery M; Tilmant M; Yzet C; Brazier F; Loreau J; Turpin J; Le Mouel JP; Goeb V; Nguyen-Khac E; Singh S; Dupas JL; Diouf M
Dig Liver Dis; 2019 Apr; 51(4):484-488. PubMed ID: 30686715
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
[TBL] [Abstract][Full Text] [Related]
37. Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease.
Glover C; Phuong L; Hinds R
J Paediatr Child Health; 2017 Jan; 53(1):94-95. PubMed ID: 28070959
[No Abstract] [Full Text] [Related]
38. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
[TBL] [Abstract][Full Text] [Related]
39. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.
Hämäläinen A; Lahdenne P; Wikström A; Aalto K; Kolho KL
Clin Exp Rheumatol; 2012; 30(4):590-1. PubMed ID: 22766212
[No Abstract] [Full Text] [Related]
40. The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab.
Zeng-Wang YM; Cares K; Thomas R; El-Baba M
Gastroenterol Nurs; 2021 Nov-Dec 01; 44(6):449-454. PubMed ID: 34690297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
